**Alert**
From April 2016, the international spelling for Indomethacin has been changed to Indometacin.

**Indication**
Closure of patent ductus arteriosus (PDA)
Prevention of severe intraventricular haemorrhage.

**Action**
Prostaglandin inhibitor. Prostaglandins are important in maintaining ductal patency in utero.

**Drug type**
Non-steroidal anti-inflammatory drug (NSAID).

**Trade name**
Indocid PDA, Indomethacin Agila

**Presentation**
1 mg powder for reconstitution.

**Dose**
IV
Single daily dose as follows:

<table>
<thead>
<tr>
<th>Post-natal Age</th>
<th>Day 1</th>
<th>Day 2</th>
<th>Day 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤ 48 hours</td>
<td>0.2 mg/kg/dose</td>
<td>0.1 mg/kg/dose</td>
<td>0.1 mg/kg/dose</td>
</tr>
<tr>
<td>&gt; 48 hours</td>
<td>0.2 mg/kg/dose</td>
<td>0.2 mg/kg/dose</td>
<td>0.2 mg/kg/dose</td>
</tr>
</tbody>
</table>

**Dose adjustment**

<table>
<thead>
<tr>
<th>Therapeutic hypothermia</th>
<th>Not applicable</th>
</tr>
</thead>
<tbody>
<tr>
<td>ECMO</td>
<td>Insufficient data to suggest dose adjustments.</td>
</tr>
<tr>
<td>Renal impairment</td>
<td>Refer to contraindications section.</td>
</tr>
<tr>
<td>Hepatic impairment</td>
<td>Insufficient data to suggest dose adjustments.</td>
</tr>
</tbody>
</table>

**Maximum dose**
0.2 mg/kg

**Total cumulative dose**
0.6 mg/kg

**Route**
IV

**Preparation**
Add 1 mL of WFI to the 1 mg powder for reconstitution. Then draw up 1 mL (1 mg) and add 9 mL WFI to make a final volume of 10 mL with a concentration of 0.1 mg/mL.

**Administration**
IV: Over 20−30 minutes.
Inspect visually for particulate matter and discolouration prior to administration.

**Monitoring**
Monitor urine output, cardiovascular status, serum biochemistry, renal function and for signs of bleeding.

**Contraindications**
Serious infection, active bleeding, thrombocytopenia or coagulopathy, necrotising enterocolitis (NEC) or intestinal perforation, significant renal dysfunction, ductal dependent congenital heart disease and pulmonary hypertension.

**Precautions**
Indomethacin is associated with transient renal impairment. Late and prolonged treatment of the ductus arteriosus with indomethacin may increase the incidence of NEC.

**Drug interactions**
Aminoglycosides: Dose may need to be modified if indomethacin affects renal function.
Digoxin: Reduces indomethacin volume of distribution – increased dose may be required.
Diuretics: Use of frusmide in combination with indomethacin may increase the incidence of renal impairment.
Systemic corticosteroids: Intestinal perforation has been described in infants treated with early dexamethasone and indomethacin.

**Adverse reactions**
Prophylactic indomethacin is associated with oliguria/anuria.
Treatment of the ductus arteriosus with indomethacin and prolonged courses of indomethacin are associated with NEC.
Gastrointestinal perforation and possibly bleeding. Extravasation.

**Compatibility**
Fluids: Sodium chloride 0.9%, water for injection.
Y site: Atropine, Cephazolin, cefotaxime, ceftazidime, clindamycin, dexamethasone, digoxin, fentanyl, fluconazole, frusmide, heparin, hydrocortisone, benzylpenicillin, potassium chloride, sodium bicarbonate.

**Incompatibility**
Fluids: Glucose 7.5%, Glucose 10%
Y-site: Amino acid solutions, adrenaline, amikacin, atracurium, aztreonam, benzoprine, buprenorphine, calcium chloride, calcium gluconate, chlorpromazine, dobutamine, dopamine, erythromycin, esmolol, gentamicin, glycopyrrolate, haloperidol lactate, hyaluramine, labetalol, magnesium sulfate, metaraminol, midazolam, morphine sulfate, noradrenaline, ondansetron, pentamidine, pethidine, phenylephrine, promethazine, protamine, suxamethonium, tobramycin, vancomycin, vasopressin, verapamil.

**Stability**
Discard unused portion. Diluted solution is stable for 6 hours at room temperature.
Indometacin (Indomethacin)
Newborn use only

**Evidence**

**Effectiveness:**
Prophylactic intravenous indomethacin in preterm infants has short-term benefits including a reduction in the incidence of symptomatic PDA, PDA surgical ligation and severe intraventricular haemorrhage (IVH). However, there is no evidence of effect on mortality or neurodevelopment5 (LOE I GOR C). Safety: Prophylactic indomethacin is associated with oliguria but not an increased creatinine or gastrointestinal side effects.

Indomethacin for asymptomatic patent ductus arteriosus: Treatment of an asymptomatic PDA with indomethacin reduced the incidence of symptomatic PDA, duration of supplemental oxygen, with no effect on mortality, IVH, retinopathy of prematurity, length of ventilation, or NEC. Safety: Renal and gastrointestinal toxicities and long term neurodevelopment were not reported10 (LOE I, GOR C).

Indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight infants: Indomethacin is as effective as ibuprofen in closing a PDA. Safety: Indomethacin increases the risk of NEC and transient renal insufficiency compared to ibuprofen.

**Dose:** Indomethacin given in total amounts for the prolonged course (6–8 doses) of 0.6–1.6 mg/kg compared with the short course 0.3–0.6 mg/kg (2–3 doses): There was no difference in efficacy between a short or prolonged course of indomethacin (LOE 1, GOR C). Safety: A prolonged course is associated with an increased risk of NEC but a decreased incidence of renal function impairment (oliguria and increased serum creatinine) 7 (LOE I, GOR B). Pharmacokinetic studies reported substantial interpatient variability11, 12 in clearance related to postnatal age2, 12. Bolus infusions of indomethacin are associated with alterations in renal, mesenteric and cerebral blood flow13. Ductus arteriosus closure rates are related to dose and indomethacin concentrations 11, 14.

**Practice points**

Indometacin (Indomethacin)

Newborn use only


**Authors Contribution**

<table>
<thead>
<tr>
<th>Original author/s</th>
<th>David Osborn, Srinivas Bolisetty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evidence Review</td>
<td>David Osborn, Tim Schindler</td>
</tr>
<tr>
<td>Expert review</td>
<td></td>
</tr>
<tr>
<td>Nursing Review</td>
<td>Eszter Jozsa, Jan Polverino</td>
</tr>
<tr>
<td>Pharmacy Review</td>
<td>Mariella De Rosa, Ushma Trivedi</td>
</tr>
<tr>
<td>ANMF Group contributors</td>
<td>Himanshu Popat, Niklant Phad, Michelle Jenkins, Thao Tran, Carmen Burman, Cindy Chen, Wendy Huynh</td>
</tr>
<tr>
<td>Final editing and review of the original</td>
<td>Ian Whyte</td>
</tr>
<tr>
<td>Electronic version</td>
<td>Cindy Chen, Ian Callander</td>
</tr>
<tr>
<td>Facilitator</td>
<td>Srinivas Bolisetty</td>
</tr>
</tbody>
</table>

**VERSION/NUMBER**

<table>
<thead>
<tr>
<th>VERSION/NUMBER</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original</td>
<td>29/09/2015</td>
</tr>
<tr>
<td>Revised 1.2</td>
<td>25/12/2016</td>
</tr>
<tr>
<td>Current 1.3</td>
<td>20/07/2020</td>
</tr>
<tr>
<td>REVIEW (5 years)</td>
<td>20/07/2025</td>
</tr>
</tbody>
</table>